The multifactorial working mechanisms by which DMF exerts its therapeutic effects in MS are not yet fully unraveled: mainly, DMF effects appear to be mediated by the activation of the pathway of the transcription factor nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) [1]. Here, NFE2L2 is linked to myeloid sarcoma.